Patent · US Active

Vaccine for prophylaxis or treatment of an allergen-driven airway pathology

US9839683B2 · kind B2 · utility

0Cited by

1References

6Claims

0Family size

Assignees

Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
INSTITUT PASTEUR DE LILLE · FR
National University of Ireland Maynooth · IE

Inventors

Camille Locht · Wannehain, FR
Bernard Mahon · Maynooth, IE
Heather Kavanagh · Dublin, IE

Key dates

Filing date	Jan 30, 2015
Grant date	Dec 12, 2017
Priority date	—
Expiry date	Feb 4, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/544
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.